# Cizzle Biotechnology: News flow driven by deals

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnology-news-flow-driven-by-deals/4121037345
- Published: 2021-12-08T07:17:15+00:00
- Author: Amilia Stone

**Cizzle Biotechnology Holdings plc** (LON:CIZ), focused on cancer diagnostics, 
was spun out of the University of York to exploit the biomarker, variant CIZ1b, 
for early detection of different forms of lung cancer. There is high medical need
for a simple blood test that allows early detection of lung cancer and potentially
improve patient outcomes. Since listing, Cizzle has been considering how to develop
a broader screening test that could be used to test for other cancers and developing
a companion diagnostic for autoimmune disease. Cizzle continues to make progress,
and has expanded the number of potential income streams through strategic partnerships.

 * **Strategy:** Cizzle Biotechnology is progressing a biomarker diagnostic assay
   for early detection of lung cancer, via a simple blood test, to improve the chances
   of survival, and to greatly reduce the need for unnecessary follow-up tests and
   tissue biopsies. Also, it is extending into related autoimmune disease with companion
   diagnostics.
 * **China:** The company has recently signed a memorandum of understanding (MoU)
   with two local partners in China for the development, supply and commercialisation
   of its early lung cancer test. A full commercial deal covering all aspects of
   this arrangement, including supply and royalties, is currently being negotiated.
 * **SGSC:** The company has already converted an MoU with St. George Street Capital(
   SGSC), a UK-based medical charity, into two full deals. The first involves the
   development of a companion diagnostic for a late-stage clinical asset; the second
   involves a commercial and royalty deal, with potential to generate royalties 
   of up to £5m.
 * **FairJourney:** In July, Cizzle signed a collaboration deal with FairJourney
   Biologics (FJB) for the development and supply of proprietary monoclonal antibodies
   and reagents that will be the foundation for protein detection in its ELISA-based
   test. This was a key step highlighted in its admission document in May.
 * **Investment summary:** Despite the deal news flow, which has expanded both the
   timing and interest in potential revenue streams, the shares have drifted since
   Cizzle Biotechnology was listed, leaving the company trading on an EV of just
   £8.3m. This suggests that there is considerable upside potential when investors
   become more aware of the company as further deals are announced and as development
   progress is reported.

[DOWNLOAD THE FULL REPORT](https://www.hardmanandco.com/research/corporate-research/news-flow-driven-by-deals/?dm_i=49CL,17JWB,6NAI95,5K1MG,1#report-download)

Share on: